301 related articles for article (PubMed ID: 34773730)
1. Validation of the LUMIPULSE automated immunoassay for the measurement of core AD biomarkers in cerebrospinal fluid.
Gobom J; Parnetti L; Rosa-Neto P; Vyhnalek M; Gauthier S; Cataldi S; Lerch O; Laczo J; Cechova K; Clarin M; Benet AL; Pascoal TA; Rahmouni N; Vandijck M; Huyck E; Le Bastard N; Stevenson J; Chamoun M; Alcolea D; Lleó A; Andreasson U; Verbeek MM; Bellomo G; Rinaldi R; Ashton NJ; Zetterberg H; Sheardova K; Hort J; Blennow K
Clin Chem Lab Med; 2022 Jan; 60(2):207-219. PubMed ID: 34773730
[TBL] [Abstract][Full Text] [Related]
2. Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer's disease.
Leitão MJ; Silva-Spínola A; Santana I; Olmedo V; Nadal A; Le Bastard N; Baldeiras I
Alzheimers Res Ther; 2019 Nov; 11(1):91. PubMed ID: 31759396
[TBL] [Abstract][Full Text] [Related]
3. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans.
Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH
Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035
[TBL] [Abstract][Full Text] [Related]
4. Analytical and clinical performances of the automated Lumipulse cerebrospinal fluid Aβ
Bayart JL; Hanseeuw B; Ivanoiu A; van Pesch V
J Neurol; 2019 Sep; 266(9):2304-2311. PubMed ID: 31179518
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of cerebrospinal fluid biomarkers measured by chemiluminescent enzyme immunoassay for Alzheimer disease diagnosis.
Agnello L; Piccoli T; Vidali M; Cuffaro L; Lo Sasso B; Iacolino G; Giglio VR; Lupo F; Alongi P; Bivona G; Ciaccio M
Scand J Clin Lab Invest; 2020 Jul; 80(4):313-317. PubMed ID: 32255379
[TBL] [Abstract][Full Text] [Related]
6. Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease.
Kang JH; Vanderstichele H; Trojanowski JQ; Shaw LM
Methods; 2012 Apr; 56(4):484-93. PubMed ID: 22503777
[TBL] [Abstract][Full Text] [Related]
7. Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.
Shaw LM; Vanderstichele H; Knapik-Czajka M; Figurski M; Coart E; Blennow K; Soares H; Simon AJ; Lewczuk P; Dean RA; Siemers E; Potter W; Lee VM; Trojanowski JQ;
Acta Neuropathol; 2011 May; 121(5):597-609. PubMed ID: 21311900
[TBL] [Abstract][Full Text] [Related]
8. Elecsys
Lifke V; Kollmorgen G; Manuilova E; Oelschlaegel T; Hillringhaus L; Widmann M; von Arnim CAF; Otto M; Christenson RH; Powers JL; Shaw LM; Hansson O; Doecke JD; Li QX; Teunissen C; Tumani H; Blennow K
Clin Biochem; 2019 Oct; 72():30-38. PubMed ID: 31129184
[TBL] [Abstract][Full Text] [Related]
9. Predicting clinical decline and conversion to Alzheimer's disease or dementia using novel Elecsys Aβ(1-42), pTau and tTau CSF immunoassays.
Blennow K; Shaw LM; Stomrud E; Mattsson N; Toledo JB; Buck K; Wahl S; Eichenlaub U; Lifke V; Simon M; Trojanowski JQ; Hansson O
Sci Rep; 2019 Dec; 9(1):19024. PubMed ID: 31836810
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility and analytical challenges in measurement of cerebrospinal fluid amyloid-β(1-42) and τ proteins as Alzheimer disease biomarkers.
Kang JH; Korecka M; Toledo JB; Trojanowski JQ; Shaw LM
Clin Chem; 2013 Jun; 59(6):903-16. PubMed ID: 23519967
[TBL] [Abstract][Full Text] [Related]
11. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment.
Janelidze S; Pannee J; Mikulskis A; Chiao P; Zetterberg H; Blennow K; Hansson O
JAMA Neurol; 2017 Dec; 74(12):1492-1501. PubMed ID: 29114726
[TBL] [Abstract][Full Text] [Related]
12. The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers.
Mattsson N; Andreasson U; Persson S; Arai H; Batish SD; Bernardini S; Bocchio-Chiavetto L; Blankenstein MA; Carrillo MC; Chalbot S; Coart E; Chiasserini D; Cutler N; Dahlfors G; Duller S; Fagan AM; Forlenza O; Frisoni GB; Galasko D; Galimberti D; Hampel H; Handberg A; Heneka MT; Herskovits AZ; Herukka SK; Holtzman DM; Humpel C; Hyman BT; Iqbal K; Jucker M; Kaeser SA; Kaiser E; Kapaki E; Kidd D; Klivenyi P; Knudsen CS; Kummer MP; Lui J; Lladó A; Lewczuk P; Li QX; Martins R; Masters C; McAuliffe J; Mercken M; Moghekar A; Molinuevo JL; Montine TJ; Nowatzke W; O'Brien R; Otto M; Paraskevas GP; Parnetti L; Petersen RC; Prvulovic D; de Reus HP; Rissman RA; Scarpini E; Stefani A; Soininen H; Schröder J; Shaw LM; Skinningsrud A; Skrogstad B; Spreer A; Talib L; Teunissen C; Trojanowski JQ; Tumani H; Umek RM; Van Broeck B; Vanderstichele H; Vecsei L; Verbeek MM; Windisch M; Zhang J; Zetterberg H; Blennow K
Alzheimers Dement; 2011 Jul; 7(4):386-395.e6. PubMed ID: 21784349
[TBL] [Abstract][Full Text] [Related]
13. Alzheimer's Disease Normative Cerebrospinal Fluid Biomarkers Validated in PET Amyloid-β Characterized Subjects from the Australian Imaging, Biomarkers and Lifestyle (AIBL) study.
Li QX; Villemagne VL; Doecke JD; Rembach A; Sarros S; Varghese S; McGlade A; Laughton KM; Pertile KK; Fowler CJ; Rumble RL; Trounson BO; Taddei K; Rainey-Smith SR; Laws SM; Robertson JS; Evered LA; Silbert B; Ellis KA; Rowe CC; Macaulay SL; Darby D; Martins RN; Ames D; Masters CL; Collins S;
J Alzheimers Dis; 2015; 48(1):175-87. PubMed ID: 26401938
[TBL] [Abstract][Full Text] [Related]
14. Concordance of Lumipulse cerebrospinal fluid t-tau/Aβ42 ratio with amyloid PET status.
Kaplow J; Vandijck M; Gray J; Kanekiyo M; Huyck E; Traynham CJ; Esquivel R; Fagan AM; Luthman J
Alzheimers Dement; 2020 Jan; 16(1):144-152. PubMed ID: 31914216
[TBL] [Abstract][Full Text] [Related]
15. Amyloid-beta(1-42), total tau, and phosphorylated tau as cerebrospinal fluid biomarkers for the diagnosis of Alzheimer disease.
Mulder C; Verwey NA; van der Flier WM; Bouwman FH; Kok A; van Elk EJ; Scheltens P; Blankenstein MA
Clin Chem; 2010 Feb; 56(2):248-53. PubMed ID: 19833838
[TBL] [Abstract][Full Text] [Related]
16. Oligomeric forms of amyloid-β protein in plasma as a potential blood-based biomarker for Alzheimer's disease.
Wang MJ; Yi S; Han JY; Park SY; Jang JW; Chun IK; Kim SE; Lee BS; Kim GJ; Yu JS; Lim K; Kang SM; Park YH; Youn YC; An SSA; Kim S
Alzheimers Res Ther; 2017 Dec; 9(1):98. PubMed ID: 29246249
[TBL] [Abstract][Full Text] [Related]
17. CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohorts.
Hansson O; Seibyl J; Stomrud E; Zetterberg H; Trojanowski JQ; Bittner T; Lifke V; Corradini V; Eichenlaub U; Batrla R; Buck K; Zink K; Rabe C; Blennow K; Shaw LM; ;
Alzheimers Dement; 2018 Nov; 14(11):1470-1481. PubMed ID: 29499171
[TBL] [Abstract][Full Text] [Related]
18. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
19. Relationship Between Cerebrospinal Fluid Alzheimer's Disease Biomarker Values Measured via Lumipulse Assays and Conventional ELISA: Single-Center Experience and Systematic Review.
Kurihara M; Kondo S; Ohse K; Nojima H; Kikkawa-Saito E; Iwata A
J Alzheimers Dis; 2024; 99(3):1077-1092. PubMed ID: 38759016
[TBL] [Abstract][Full Text] [Related]
20. Herpes simplex virus alters Alzheimer's disease biomarkers - A hypothesis paper.
Goldhardt O; Freiberger R; Dreyer T; Willner L; Yakushev I; Ortner M; Förstl H; Diehl-Schmid J; Milz E; Priller J; Ramirez A; Magdolen V; Thaler M; Grimmer T
Alzheimers Dement; 2023 May; 19(5):2117-2134. PubMed ID: 36396609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]